Login to Your Account



PDL's Shares Drop On Xolair Patent Dispute With Genentech

By Brady Huggett


Monday, August 18, 2003
Based on a cross-licensing patent agreement with Genentech Inc. related to humanized antibodies signed nearly five years ago, Protein Design Labs Inc. and company followers were happily eyeing certain Genentech product sales and the potential for more as other products received approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription